India Pharma Outlook Team | Wednesday, 30 September 2026
India’s healthcare capacity is expanding as private hospital chains commit capital to new beds and specialized care infrastructure.
Global Health, which operates hospitals under the Medanta brand, has acquired a 10,560-square-metre land parcel in Ghaziabad for Rs 165.82 crore to develop a 350-plus-bed hospital.
The proposed facility will strengthen Medanta’s Delhi-NCR presence and serve patients across Ghaziabad, eastern Delhi, Meerut and parts of western Uttar Pradesh.
While the immediate development is a hospital expansion, the wider significance lies in how additional organized capacity can influence demand for pharmaceuticals, diagnostics, medical devices and specialized healthcare services across India.
Global Health’s proposed Ghaziabad hospital will add more than 350 beds to its network and expand access to advanced healthcare in a rapidly developing Delhi-NCR market.
The project is subject to statutory and customary approvals as well as approval from the company’s Board.
Global Health said the facility is intended to cater to demand from Ghaziabad and neighbouring markets, including eastern Delhi, Meerut, Saharanpur, Hapur, Bulandshahr and western Uttar Pradesh.
Global Health Group CEO and Director Pankaj Sahni said the region has undergone significant urban and economic development and is seeing increasing demand for advanced and specialized healthcare services.
The company had 3,737 installed beds across six hospitals as of June 30, 2026, alongside five upcoming hospitals.
Also Read: Why Clinical Evidence Matters More in MedTech Commercialization
Medanta’s project forms part of a much broader hospital capacity expansion underway across India. ICRA expects 18 large private hospital chains to add more than 34,000 beds between FY2026 and FY2030, involving an estimated Rs 40,000 crore of investment.
The additions are expected to increase their combined capacity by around 48-50 percent from March 2025 levels. ICRA also noted that tier-II and tier-III cities are expected to see greater traction alongside metropolitan markets.
This expansion reflects a continuing demand-supply gap in organized healthcare. ICRA said private hospitals account for around 59-60 percent of available hospital beds, while dependence on private healthcare remains high because of constraints within public healthcare infrastructure.
The capacity expansion has implications beyond bed availability. New and larger hospitals require a wider ecosystem of medicines, diagnostics, medical devices and clinical consumables.
As organized hospitals expand specialized departments, potential demand can increase across areas such as oncology, cardiology, critical care, anti-infectives, hospital injectables and complex therapies.
For pharmaceutical companies, this makes hospital expansion an important downstream component of India’s healthcare market.
However, the impact will vary according to each hospital’s specialty mix, procurement model and patient profile rather than translating directly into a fixed increase in drug consumption.
The significance of projects such as Medanta’s Ghaziabad facility is therefore the creation of additional organized healthcare infrastructure alongside the pharmaceutical ecosystem.
ICRA expects hospital investments to continue across metros as well as tier-II and tier-III cities, with capacity additions aimed at underserved demand centers.
Pharmaceutical growth is increasingly linked not only to drug manufacturing and product pipelines, but also to the expansion of hospitals, diagnostics and specialized treatment infrastructure that ultimately provides channels for advanced therapies to reach patients.
.jpg)
